Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) shares crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of C$10.11 and traded as low as C$9.09. Fennec Pharmaceuticals shares last traded at C$9.40, with a volume of 683 shares changing hands.
Analyst Upgrades and Downgrades
Separately, B. Riley Financial upgraded shares of Fennec Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, February 11th. One investment analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Strong Buy".
Get Our Latest Analysis on Fennec Pharmaceuticals
Fennec Pharmaceuticals Price Performance
The stock has a market capitalization of C$324.07 million, a price-to-earnings ratio of -27.65 and a beta of 3.09. The business has a fifty day moving average of C$10.11 and a 200 day moving average of C$10.82.
Insider Activity at Fennec Pharmaceuticals
In other Fennec Pharmaceuticals news, Director Rostislav Christov Raykov purchased 15,598 shares of the firm's stock in a transaction dated Monday, February 2nd. The shares were acquired at an average price of C$3.37 per share, with a total value of C$52,565.26. Following the purchase, the director directly owned 2,719,643 shares in the company, valued at approximately C$9,165,196.91. This trade represents a 0.58% increase in their position. 16.20% of the stock is currently owned by company insiders.
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
